Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

This observational study evaluated the safety of testosterone replacement therapy (TRT) in 31 men with symptomatic hypogonadism after undergoing brachytherapy for early-stage prostate cancer. Over a median follow-up of 5 years post-brachytherapy, TRT increased median testosterone levels from 188 ng/dL to 498 ng/dL without causing biochemical recurrence. No patients experienced